Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Theralase Technologies ( (TSE:TLT) ) has issued an announcement.
Theralase Technologies has raised C$2.66 million through a non-brokered private placement of 6,404,700 units and a C$1 million revolving line of credit with Desjardins, issuing common shares and five-year warrants and paying a modest finder’s fee in equity and warrants, with all new securities subject to a standard hold period and exchange approval. The fresh capital, which includes insider participation structured under minority protection rules, strengthens the company’s balance sheet and will fund its ongoing Phase II trial in BCG-unresponsive non-muscle invasive bladder cancer, GLP toxicology work for Rutherrin, general corporate needs and preparations to seek Health Canada and FDA marketing approvals for its light-activated drug Ruvidar in 2026, potentially advancing its regulatory and commercial trajectory in bladder cancer treatment.
The most recent analyst rating on (TSE:TLT) stock is a Hold with a C$0.25 price target. To see the full list of analyst forecasts on Theralase Technologies stock, see the TSE:TLT Stock Forecast page.
Spark’s Take on TLT Stock
According to Spark, TipRanks’ AI Analyst, TLT is a Neutral.
The score is held down primarily by weak financial performance—very large losses versus a small and declining revenue base, ongoing cash burn, and substantial equity erosion. Technicals provide some support with strong recent momentum (price above major moving averages and positive MACD), but elevated RSI suggests the move may be stretched. Valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on TLT stock, click here.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical-stage pharmaceutical company focused on the research and development of energy-activated small molecules designed to safely and effectively destroy cancer, bacteria and viruses. The company’s lead programs target bladder cancer, including Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer carcinoma in situ, and it is advancing light-activated drug candidates such as Ruvidar and Rutherrin within this oncology niche.
Average Trading Volume: 157,791
Technical Sentiment Signal: Buy
Current Market Cap: C$65.55M
See more insights into TLT stock on TipRanks’ Stock Analysis page.